Following The Money: Institution’s Growing Stake In Fate Therapeutics Inc (NASDAQ: FATE)

Fate Therapeutics Inc (FATE) concluded trading on Thursday at a closing price of $6.11, with 2.8 million shares of worth about $17.12 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 79.71% during that period and on Thursday the price saw a gain of about 9.89%. Currently the company’s common shares owned by public are about 97.29M shares, out of which, 92.59M shares are available for trading.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 11 times over the past 12 months. They bought 443,844 shares in 3 of the transactions. In 8 selling transactions, insiders dumped 44,741 shares.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

However, the stock later moved at a day high price of 6.16, or with a gain of 9.89%. Stock saw a price change of -9.62% in past 5 days and over the past one month there was a price change of 38.55%. Year-to-date (YTD), FATE shares are showing a performance of 63.37% which decreased to -10.67% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.63 but also hit the highest price of $6.99 during that period. The average intraday trading volume for Fate Therapeutics Inc shares is 2.42 million. The stock is currently trading 18.62% above its 20-day simple moving average (SMA20), while that difference is up 56.23% for SMA50 and it goes to 64.48% higher than SMA200.

Fate Therapeutics Inc (NASDAQ: FATE) currently have 97.29M outstanding shares and institutions hold larger chunk of about 108.33% of that.

The stock has a current market capitalization of $602.45M and its 3Y-monthly beta is at 1.63. It has posted earnings per share of -$1.77 in the same period. It has Quick Ratio of 8.81 while making debt-to-equity ratio of 0.26. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FATE, volatility over the week remained 13.31% while standing at 11.74% over the month.

Analysts are in expectations that Fate Therapeutics Inc (FATE) stock would likely to be making an EPS of -$0.52 in the current quarter, while forecast for next quarter EPS is -$0.52 and it is -$2.03 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.71 which is -$0.32 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.58 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 41.17% while it is estimated to decrease by -16.94% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on March 27, 2023 offering an Equal weight rating for the stock and assigned a target price of $6 to it.

Most Popular

Related Posts